EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O.

GlobeNewsWire • Feb 5, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

GlobeNewsWire • Jan 16, 2026

EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m.

GlobeNewsWire • Jan 7, 2026

EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know

Does EyePoint (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 22, 2025

3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026

EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.

Zacks Investment Research • Dec 22, 2025

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT/10:30 a.m. ET.

GlobeNewsWire • Dec 17, 2025

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the Company's ongoing pivotal Phase 3 program evaluating DURAVYU for the treatment of wet age-related macular degeneration (wet AMD).

GlobeNewsWire • Nov 19, 2025

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. ( EYPT ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning. My name is Antoine, and I will be your conference operator today.

Seeking Alpha • Nov 5, 2025

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –

GlobeNewsWire • Nov 5, 2025